Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Common Equity (2020 - 2025)

Historic Common Equity for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $976.6 million.

  • Janux Therapeutics' Common Equity rose 4884.15% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 4884.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 19701.87% up from last year.
  • Janux Therapeutics' Common Equity amounted to $976.6 million in Q3 2025, which was up 4884.15% from $990.5 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Common Equity registered a high of $1.0 billion during Q4 2024, and its lowest value of $299.5 million during Q2 2023.
  • For the 5-year period, Janux Therapeutics' Common Equity averaged around $542.0 million, with its median value being $371.5 million (2021).
  • As far as peak fluctuations go, Janux Therapeutics' Common Equity skyrocketed by 260257.55% in 2021, and later plummeted by 1289.8% in 2023.
  • Quarter analysis of 5 years shows Janux Therapeutics' Common Equity stood at $366.3 million in 2021, then fell by 12.44% to $320.7 million in 2022, then grew by 7.36% to $344.3 million in 2023, then surged by 197.02% to $1.0 billion in 2024, then fell by 4.52% to $976.6 million in 2025.
  • Its Common Equity was $976.6 million in Q3 2025, compared to $990.5 million in Q2 2025 and $1.0 billion in Q1 2025.